NeuroDiscovery (NDL)

Shares / Stock Code


Stock Exchange / Sharemarket


NeuroDiscovery (NDL) is a global research and development company operating in Life Science. The company focuses on the commercialization and development of opportunities in the field of neurology. NDL was incorporated on 14 April 2005. NDL was listed on the Australian stockmarket (ASX) in August 2005 and raised $1.5 million via its IPO. The company aims to identify and evaluate investment opportunities in the Life Science sector and either invest in or acquire commercially attractive projects which the Directors believe generate shareholder value.

NeuroDiscovery has acquired 100% of NeuroSolutions Ltd, a UK based biotechnology company which is a leading provider of electro physiology services to the bio pharmaceutical industry and has a pipeline of drug candidates under development with a current focus on the treatment of pain.NDL's major customers include strong working relationships with large multinational pharmaceuticals and biotechnology companies. Competitors consist of businesses that operate in the area of neuropathic pain.

NDL operates in two segments: contract services, which operates in the field of neurology providing specialist services to the bio pharmaceutical sector, and research and development, which is engaged in progressing a pipeline of potential compounds for the treatment of neuropathic pain. The Company has operations in Australia and the United Kingdom.

NeuroDiscovery (NDL) Products and Services

  • Neurology Research and Development

NeuroDiscovery (NDL) Locations and Subsidiaries

NeuroDiscovery Head Office
Level 11, 225 St George's Terrace, PERTH,
Phone: (08)9226 4033
Fax: (08)9226 0333

NeuroDiscovery (NDL) Share Price

Submitted by ASX Listed Company on 14 May, 2010 - 16:54